You are here

Weaker Antibody Response to First COVID-19 Vaccine Dose Found in Long-Term Care Residents

A single dose of the Pfizer-BioNTech COVID-19 vaccine produces a much weaker antibody response in long-term care residents than it does in younger healthy adults, new research has found.

The pre-print findings, yet to be peer-reviewed, raise questions about the optimal timing of the second dose of vaccine for older adults.

“Results from this study in long-term care facilities in Vancouver reveal that individuals of advanced age, following the first dose of a two-dose vaccination regimen, are less able to generate as strong an antibody response, both in terms of magnitude and function, compared to adults of younger age,” says Dr. Marc Romney, clinical associate professor in University of British Columbia’s department of pathology and laboratory medicine, and medical leader for medical microbiology and virology at St. Paul’s Hospital, Providence Health Care. “It will be important to assess whether this observation extends to older persons living in the community as this may inform the optimal timing of the second dose for this population.”

Find out more on this topic here at Weaker antibody response to first COVID-19 vaccine dose found in long-term care residents | The Daily Scan (